IOB - Delayed Quote USD
Sanofi (0A2V.IL)
55.52
+1.18
+(2.17%)
At close: May 2 at 6:59:05 PM GMT+1
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Sep 2022) | Next Qtr. (Dec 2022) | Current Year (2022) | Next Year (2023) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 2 | 3 |
| Avg. Estimate | 1.34 | 0.87 | 4.3 | 4.41 |
| Low Estimate | 1.34 | 0.87 | 4.25 | 4.1 |
| High Estimate | 1.34 | 0.87 | 4.35 | 4.7 |
| Year Ago EPS | 1.28 | 0.79 | 3.88 | 4.3 |
Revenue Estimate
| Currency in USD | Current Qtr. (Sep 2022) | Next Qtr. (Dec 2022) | Current Year (2022) | Next Year (2023) |
|---|---|---|---|---|
| No. of Analysts | 4 | 3 | 4 | 5 |
| Avg. Estimate | 11.78B | 11.07B | 43.17B | 45.16B |
| Low Estimate | 11.62B | 10.82B | 42.79B | 44.02B |
| High Estimate | 11.87B | 11.33B | 43.69B | 46.44B |
| Year Ago Sales | 11.85B | 11.42B | 44.63B | 43.17B |
| Sales Growth (year/est) | -0.60% | -3.10% | -3.30% | 4.60% |
Earnings History
| Currency in USD | 9/30/2021 | 12/31/2021 | 3/31/2022 | 6/30/2022 |
|---|---|---|---|---|
| EPS Est. | 1.17 | 0.72 | 0.92 | 0.87 |
| EPS Actual | 1.28 | 0.79 | 1.09 | 0.92 |
| Difference | 0.11 | 0.07 | 0.17 | 0.05 |
| Surprise % | 9.40% | 9.70% | 18.50% | 5.70% |
EPS Trend
| Currency in USD | Current Qtr. (Sep 2022) | Next Qtr. (Dec 2022) | Current Year (2022) | Next Year (2023) |
|---|---|---|---|---|
| Current Estimate | 1.34 | 0.87 | 4.3 | 4.41 |
| 7 Days Ago | 1.34 | 0.87 | 4.3 | 4.41 |
| 30 Days Ago | 1.33 | 0.87 | 4.22 | 4.41 |
| 60 Days Ago | 1.31 | 0.84 | 4.17 | 4.41 |
| 90 Days Ago | 1.31 | 0.84 | 4.17 | 4.41 |
EPS Revisions
| Currency in USD | Current Qtr. (Sep 2022) | Next Qtr. (Dec 2022) | Current Year (2022) | Next Year (2023) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 1 | -- | -- | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| 0A2V.IL | 4.70% | 10.10% | 10.80% | 2.60% |
| S&P 500 | 12.40% | 3.81% | 8.28% | 13.79% |
Upgrades & Downgrades
| Initiated | Goldman Sachs: Neutral | 3/21/2025 |
| Maintains | Argus Research: Buy to Buy | 7/26/2024 |
| Initiated | Morgan Stanley: Equal-Weight | 1/23/2024 |
| Maintains | Argus Research: Buy | 3/27/2023 |
| Upgrade | Deutsche Bank: Sell to Hold | 8/12/2022 |
| Upgrade | SVB Leerink: Market Perform to Outperform | 9/27/2021 |
Related Tickers
DSNKY Daiichi Sankyo Company, Limited
25.91
-0.12%
BAYRY Bayer Aktiengesellschaft
6.74
-0.15%
RHHBY Roche Holding AG
41.08
-0.12%
BIIB Biogen Inc.
123.53
+2.15%
GSK GSK plc
39.07
+0.83%
AZN AstraZeneca PLC
72.44
+2.74%
GILD Gilead Sciences, Inc.
103.68
+0.42%
BMY Bristol-Myers Squibb Company
50.57
+1.94%
OGN Organon & Co.
9.59
+1.48%
LLY Eli Lilly and Company
823.62
+3.72%